Beta Bionics Launches iLet Integration with Eversense 365 CGM
Beta Bionics has officially launched the integration of its iLet Bionic Pancreas with the Eversense 365 continuous glucose monitoring system.
Stocks · News reference
Beta Bionics management discussed Q3 2026 performance, updated guidance, and product development timelines during the Stifel 2026 Healthcare Conference.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Beta Bionics has officially launched the integration of its iLet Bionic Pancreas with the Eversense 365 continuous glucose monitoring system.
Beta Bio reported Q3 2026 net sales of $35.5 million with strong pharmacy channel momentum. The company received FDA clearance for Mint, its tubeless patch pump launching in Q1 2027, expected to drive significant growth. Management raised full-year 2026 revenue guidance and highlighted that Mint's gross margins could exceed current patch pump products within three years. The company is resubmitting its 3D Intelligence dosing algorithm application after addressing FDA feedback.
Beta Bionics, Inc. management will participate in several healthcare-focused investor conferences throughout November and December 2026.
A securities class action lawsuit has been filed against Beta Bionics, Inc. for investors who purchased stock between July 30, 2025 and February 24, 2026. The complaint alleges the company received thousands of complaints about serious, life-threatening hypoglycemia incidents caused by device malfunctions in its iLet insulin pump, which were not properly disclosed. The FDA issued a warning letter on February 24, 2026 detailing violations and contradicting the company's prior statements about the severity of patient incidents. The deadline to move the court to become lead plaintiff is November 3, 2026.
Beta Bionics reported Q3 2026 net sales of $35.5 million and updated its full-year 2026 revenue guidance to $124 million–$126 million. The company also announced the withdrawal of its 510(k) application for the 3D Intelligence algorithm to provide additional validation data.
A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels and causing hundreds of life-threatening hypoglycemic events. The company allegedly failed to disclose thousands of customer complaints to the FDA and misrepresented the scope of FDA Form 483 findings. Investors who purchased stock between July 30, 2025 and February 24, 2026 can join the lawsuit with a November 3, 2026 deadline to request lead plaintiff status.